Peptide
Pasireotide (Signifor)
Pasireotide is a novel multi-receptor-targeted somatostatin analog with high affinity for somatostatin receptor subtypes 1, 2, 3, and 5. FDA-approved in 2012, it is the first pituitary-directed medication for Cushing's disease. Available as twice-daily subcutaneous injection (Signifor) and long-acting monthly injection (Signifor LAR) for acromegaly. The Phase III PASPORT trial demonstrated significant urinary free cortisol normalization in Cushing's disease patients.
- Updated
- How we grade
- 47 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade A
- Conditions studied
- 2
- Outcomes
- 10
- Graded outcomes
- 5131
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
General
Key findings
- Cushing's Disease SymptomsImproves (the measure goes down)
- ACTH SecretionImproves (the measure goes down)
- Urinary Free Cortisol NormalizationImproves (the measure goes down)
Studies cited
47 studies from PubMed
- Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis.
- Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia.
- Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature.
- Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis.
- Efficacy and safety of pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis.
- Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line.
- Pasireotide Versus Octreotide in Preventing Complications After Simultaneous Pancreas-Kidney Transplantation.
- Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature.
- Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis.
- Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion.
- Pasireotide treatment for severe congenital hyperinsulinism due to a homozygous ABCC8 mutation.
- Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study.
- Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis.
- Risk factors and management of pasireotide-associated hyperglycemia in acromegaly.
- Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
- Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide.
- Efficacy of Pasireotide for Prevention of Postoperative Pancreatic Fistula in Pancreatic Surgery: a Systematic Review and Meta-analysis.
- Meta-analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula.
- Meta-Analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula.
- Tumor-Directed Therapeutic Targets in Cushing Disease.
- Pasireotide protects mammalian cochlear hair cells from gentamicin ototoxicity by activating the PI3K-Akt pathway.
- Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells.
- Pasireotide in the treatment of neuroendocrine tumors: a review of the literature.
- Multidisciplinary management of refractory insulinomas.
- Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial
- Medical Therapy with Pasireotide in Recurrent Cushing's Disease: Experience of Patients Treated for At Least 1 Year at a Single Center
- Pasireotide - Mechanism of Action and Clinical Applications
- Diabetes in Cushing Disease.
- Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
- Pasireotide for malignant insulinoma.
- Hyperglycemia in pasireotide-treated patients with acromegaly and its treatment.
- Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly.
- Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.
- Pasireotide induced adrenal insufficiency.
- Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study
- Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations.
- Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
- Pasireotide LAR for acromegaly (PAOLA Study): a randomized, placebo-controlled, phase III study with a 25-week extension phase
- Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations.
- Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience.
- Pasireotide: a review of its use in Cushing's disease
- Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.
- A 12-month phase 3 study of pasireotide in Cushing's disease
- Medical treatment of Cushing's disease: somatostatin analogues and pasireotide
- Pasireotide for the treatment of Cushing's disease
- Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial
- Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease